Director Frances Arnold of Generate Biomedicines, Inc. filed a Form 144 notice of proposed sale on October 29, 2026, covering 11,409 shares of common stock with an aggregate market value of $184,732.91.

Key Highlights

  • Proposed sale: Frances Arnold, a director, intends to sell 11,409 shares of Generate Biomedicines common stock through Fidelity Brokerage Services LLC.
  • Aggregate market value: The 11,409 shares carry an aggregate market value of $184,732.91, according to the filing.
  • Shares outstanding: Generate Biomedicines had 128,352,436 shares of common stock outstanding as reported in the notice.
  • Acquisition source: The shares were acquired on September 23, 2020 via restricted stock vesting from the issuer, with compensation cited as the nature of payment.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of March 13, 2026.
  • Prior sales: Arnold sold 1,000 shares on September 1, 2026 for gross proceeds of $16,002.00, and 32,210 shares on September 2, 2026 for gross proceeds of $520,630.62, in the three months preceding this notice.

Generate Biomedicines Director Arnold Discloses Proposed Common Stock Sale Under Rule 144

Generate Biomedicines, Inc. (NASDAQ:GENB), headquartered at 101 South Street, Suite 900, Somerville, Massachusetts, is the subject of a Form 144 notice filed on October 29, 2026. Director Frances Arnold is the person for whose account the securities are proposed to be sold. The filing lists Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, Rhode Island 02917, as the named broker for the transaction.

According to the filing, the 11,409 shares of common stock targeted for sale were originally acquired on September 23, 2020 through restricted stock vesting from the issuer. The nature of payment was listed as compensation. The approximate date of the proposed sale is October 29, 2026. The filing also discloses that Arnold adopted a written trading plan pursuant to Rule 10b5-1 on March 13, 2026, with the notice signed by Jennifer Ruchti as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Frances Arnold.

The filing further reports Arnold's prior sales activity over the preceding three months. On September 1, 2026, 1,000 shares of common stock were sold for gross proceeds of $16,002.00. On September 2, 2026, an additional 32,210 shares were sold for gross proceeds of $520,630.62. Both transactions are listed at the same Somerville, Massachusetts address associated with the issuer.

What Was Disclosed

A Form 144 notice was filed on October 29, 2026 by director Frances Arnold, disclosing a proposed sale of 11,409 shares of Generate Biomedicines common stock valued at $184,732.91, acquired through restricted stock vesting in 2020, and conducted under a Rule 10b5-1 plan adopted March 13, 2026.